EA009872B1 - АНТИ-Aβ АНТИТЕЛА - Google Patents

АНТИ-Aβ АНТИТЕЛА Download PDF

Info

Publication number
EA009872B1
EA009872B1 EA200601545A EA200601545A EA009872B1 EA 009872 B1 EA009872 B1 EA 009872B1 EA 200601545 A EA200601545 A EA 200601545A EA 200601545 A EA200601545 A EA 200601545A EA 009872 B1 EA009872 B1 EA 009872B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
peptide
cells
antibodies
secretase
Prior art date
Application number
EA200601545A
Other languages
English (en)
Russian (ru)
Other versions
EA200601545A1 (ru
Inventor
Рональд Брэдли Дематтос
Ума Кучибхотла
Си-Чиун Ян
Дон Б. Макклур
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200601545A1 publication Critical patent/EA200601545A1/ru
Publication of EA009872B1 publication Critical patent/EA009872B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
EA200601545A 2004-02-23 2005-02-17 АНТИ-Aβ АНТИТЕЛА EA009872B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23
PCT/US2005/005198 WO2005082939A2 (en) 2004-02-23 2005-02-17 Anti-abeta antibody

Publications (2)

Publication Number Publication Date
EA200601545A1 EA200601545A1 (ru) 2007-02-27
EA009872B1 true EA009872B1 (ru) 2008-04-28

Family

ID=34910810

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601545A EA009872B1 (ru) 2004-02-23 2005-02-17 АНТИ-Aβ АНТИТЕЛА

Country Status (20)

Country Link
US (1) US20070190046A1 (enExample)
EP (1) EP1720909B1 (enExample)
JP (1) JP4851348B2 (enExample)
KR (2) KR100889430B1 (enExample)
CN (1) CN1922209B (enExample)
AT (1) ATE534667T1 (enExample)
AU (1) AU2005217596B2 (enExample)
BR (1) BRPI0507856A (enExample)
CA (1) CA2556436C (enExample)
CY (1) CY1112162T1 (enExample)
DK (1) DK1720909T3 (enExample)
EA (1) EA009872B1 (enExample)
ES (1) ES2375627T3 (enExample)
IL (1) IL177611A (enExample)
NO (1) NO20064239L (enExample)
PL (1) PL1720909T3 (enExample)
PT (1) PT1720909E (enExample)
SI (1) SI1720909T1 (enExample)
UA (1) UA93181C2 (enExample)
WO (1) WO2005082939A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
NZ568012A (en) 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
RU2498999C2 (ru) 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HUE033325T2 (en) * 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
ES2610474T3 (es) 2007-01-11 2017-04-27 Michael Bacher Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
PL2238166T3 (pl) 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
EP2376120A2 (en) 2008-11-25 2011-10-19 Biogen Idec MA Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
BR112012009997A2 (pt) 2009-11-12 2019-09-24 Genentech Inc ''método para aumentar a densidade de espinhas dentriticas nos neurônios de um paciente com um distúrbios cognitivo ou psiquiatrico,método de manutenção da cognição em um sujeito durante o processo de envelhecimento,uso de um antagonista de dr6 na preparação de um medicamento para uso em um paciente com um disturbio cognitivo uo psiquíatrico e uso de um antagonista de p75 na preparação de um medicamento para uso em um paciente com um distúrbio cognitivo ou psiquiátrico''
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
SI3339323T1 (sl) * 2010-08-12 2019-12-31 Eli Lilly And Company Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
EP2892506B1 (en) 2012-09-07 2021-11-03 Massachusetts Eye & Ear Infirmary Treating hearing loss with the gamma-secretase inhibitor ly411575
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
KR102362222B1 (ko) 2016-05-16 2022-02-11 더 제너럴 하스피탈 코포레이션 폐 상피 공학에서 인간 기도 줄기 세포
JP2019524788A (ja) * 2016-08-11 2019-09-05 イーライ リリー アンド カンパニー アミノチアジンおよびｂａｃｅ１阻害剤としてのそれらの使用
MD3672631T3 (ro) 2017-08-22 2023-09-30 Biogen Ma Inc Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CA3243602A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046237A2 (en) * 2000-12-06 2002-06-13 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
WO2002088306A2 (en) * 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9711537B (en) 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
EA006606B1 (ru) * 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046237A2 (en) * 2000-12-06 2002-06-13 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
WO2002088306A2 (en) * 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARNES L. M. ET AL.: "Advances in animal cell recombinant protein production: GS-NSO expression system", CYTOTECHNOLOGY, vol. 32, no. 2, February 2000 (2000-02), pages 109-123, XP002301322, ISSN: 0920-9069, the whole document *
CHAUHAN NEELIMA B. ET AL.: "Intracerebroventricular passive immunization with anti-Abeta antibody 1n Tg2576", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 74, no. 1, 1 October 2003 (2003-10-01), pages 142-147, XP002339442, ISSN: 0360-4012, abstract, page 143, right-hand column, last paragraph - page 144, left-hand column, paragraph 1 *
MILLER DAVID L. ET AL.: "Humoral immune response to fibrillar beta-amyloid peptide", BIOCHEMISTRY, vol. 42, no. 40, 14 October 2003 (2003-10-14), pages 11682-11692, XP002339443, ISSN: 0006-2960, page 11683, right-hand column, paragraph 2 - paragraph 3 *
YOO E. M. ET AL.: "Myeloma expression systems", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V..AMSTERDAM, NL, vol. 261, no. 1-2, 1 March 2002 (2002-03-01), pages 1-20, XP004341264, ISSN: 0022-1759, abstract, page 3, left-hand column, line 1 - line 13 table 1, page 13, right-hand column, last paragraph *

Also Published As

Publication number Publication date
EA200601545A1 (ru) 2007-02-27
WO2005082939A3 (en) 2005-10-27
CA2556436A1 (en) 2005-09-09
ES2375627T3 (es) 2012-03-02
BRPI0507856A (pt) 2007-07-10
WO2005082939A2 (en) 2005-09-09
AU2005217596B2 (en) 2012-01-19
IL177611A0 (en) 2006-12-10
AU2005217596A1 (en) 2005-09-09
KR100889430B1 (ko) 2009-03-23
EP1720909A2 (en) 2006-11-15
DK1720909T3 (da) 2012-01-30
PL1720909T3 (pl) 2012-04-30
CY1112162T1 (el) 2015-12-09
CA2556436C (en) 2014-04-01
KR20090005410A (ko) 2009-01-13
JP4851348B2 (ja) 2012-01-11
CN1922209B (zh) 2012-09-05
CN1922209A (zh) 2007-02-28
EP1720909B1 (en) 2011-11-23
SI1720909T1 (sl) 2012-01-31
KR20060126785A (ko) 2006-12-08
NO20064239L (no) 2006-11-20
ATE534667T1 (de) 2011-12-15
US20070190046A1 (en) 2007-08-16
IL177611A (en) 2013-05-30
PT1720909E (pt) 2011-12-23
JP2008500279A (ja) 2008-01-10
UA93181C2 (ru) 2011-01-25

Similar Documents

Publication Publication Date Title
AU2005217596B2 (en) Anti-ABeta antibody
JP4540132B2 (ja) Ｉｌ−６レセプター抗体を含んでなる筋蛋白分解抑制剤
JP2023116817A (ja) 抗体製剤および方法
Madri et al. Isolation and tissue localization of type AB2 collagen from normal lung parenchyma
KR20250061718A (ko) 항-인플루엔자 b 바이러스 항체, 인플루엔자 b 바이러스의 검출용 시약 및 키트
EA012162B1 (ru) Способ рефолдинга рекомбинантных антител
EA032054B1 (ru) Моноклональное антитело или его антигенсвязывающий фрагмент, его применения, клеточная линия гибридомы для его получения, фармацевтическая композиция, содержащая моноклональное антитело или его антигенсвязывающий фрагмент, способ диагностики in vitro амилоид-ассоциированного заболевания и набор для его осуществления
Richter et al. A study of two types of ferritin from rat hepatomas
WO2025180021A1 (zh) 一种抗人与鼠TfR的抗体或其抗原结合片段及其用途
DE60128452T2 (de) Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung
Salant et al. Altered glomerular permeability induced by F (ab′) 2 and Fab′ antibodies to rat renal tubular epithelial antigen
EP0131834B1 (en) Monoclonal antibody having specificity to only one type of an isozyme of human cardiac myosin heavy chain
AU603053B2 (en) Novel lymphokine, monoclonal antibody specific to the lymphokine, and their production and uses
DE69229230T2 (de) Antikörpertest zur erkennung von alkoholikern und zur überwachung der alkoholaufnahme
Natorio et al. Role of dipeptidyl peptidase IV (gp 108) in passive Heymann nephritis. Use of dipeptidyl peptidase IV-deficient rats
JPH08510446A (ja) 組換え骨形成タンパク質を生成するための方法および組成物
US20030186335A1 (en) Monoclonal antibodies, hybridomas, cell isolation method, isolated cells and immunological diagnostic method
JP2643040B2 (ja) モノクローナル抗体
MXPA06009560A (en) Anti-abeta antibody
JPH0794475B2 (ja) 純粋なエリスロポエチンの製造法
AU2012201856A1 (en) Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
TW202140555A (zh) 失智症之預防或治療劑
JPH01171495A (ja) モノクローナル抗体及びそれを用いる定量法
WO1989001947A1 (fr) Proteine derivee d&#39;un corps vivant
JPH0560359B2 (enExample)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU